by qfrsolutions | Feb 1, 2018 | News
Source: LinkedIn QFR Solutions has earned another Top spot in LinkedIn’s Top 25 Most Socially Engaged Staffing Agencies. This is the second top spot for QFR Solutions since the inception of the awards in 2016. QFR ranked #2 in 2017 and #1 in 2016. There were nearly...
by qfrsolutions | Jan 8, 2018 | News
Source: Forbes Last night, Celgene announced that it is buying Impact BioMedicines, a small biotech developing a drug to compete with the blockbuster blood cancer drug Jakafi, sold by Incyte and Novartis, in an announcement timed to coincide with the annual J.P....
by qfrsolutions | Dec 18, 2017 | News
Source: Aclaris Therapeutics MALVERN, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ESKATA™...
by qfrsolutions | Dec 5, 2017 | News
Source: Business Wire December 01, 2017 01:05 AM Eastern Standard Time HYDERABAD, India & PRINCETON, N.J. & MALVERN, Pa.– Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), through its wholly owned subsidiary Promius Pharma, LLC,...
by qfrsolutions | Nov 3, 2017 | News
Source: FierceBiotech AbbVie has posted positive phase 3 psoriasis data on potential blockbuster risankizumab. The IL-23 antibody easily outperformed Johnson & Johnson’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year. Risankizumab...
by qfrsolutions | Oct 1, 2017 | News
Source: PR Newswire Dermavant Sciences, a biopharmaceutical company focused on developing innovative therapies for dermatologic conditions, today announced the appointment of Vince Ippolito as President and Chief Operating Officer. “I am extremely pleased to...
